MedTrace Logo

PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

NCT03647072 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-08-27

No results posted yet for this study

Summary

The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.

Conditions

Interventions

DRUG

CHOP

CHOP only

DRUG

CHOP Plus Lanzoprazole

CHOP plus Lanzoprazole 60 mg

DRUG

CHOP Plus Famotidine

CHOP Plus Famotidine 40 mg

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Sahar K Hegazy, Prof · Clinical pharmacy Department- Tanta University

  • Sahar M El-Haggar, prof · Clinical pharmacy Department- Tanta University

  • Suzan A Alhassanin, Ph D · Clinical Oncology Department-Menoufia University

  • Eman I A El berri, Msc · Clinical pharmacy Department-Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2027-10-31
Completion
2027-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03647072 on ClinicalTrials.gov